Why One Value Fund Just Bought $30 Million of a Diagnostics Stock Down 90% From Pandemic-Era Highs

New York City-based Newtyn Management bought 994,332 shares of QuidelOrtho Corporation in the third quarter, increasing its position by an estimated $30.4 million. At quarter-end, the firm reported holding 2.7 million QDEL shares valued at $79.5 million.

The Motley Fool • Dec 7, 2025

QuidelOrtho Corporation (QDEL) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

QuidelOrtho Corporation (QDEL) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 3, 2025

QuidelOrtho To Participate In Upcoming Investor Conferences

SAN DIEGO , Nov. 24, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global leader of in vitro diagnostics, announced today that members of its management team will participate in two upcoming investor conferences: Evercore ISI 8th Annual Healthcare Conference, Tuesday, December 2, 2025 Members of QuidelOrtho's management team are scheduled to participate in a fireside chat at 10:00 a.m. ET / 7:00 a.m.

PRNewsWire • Nov 24, 2025

The Power of Prevention: Detecting Diabetes Before It Strikes

SAN DIEGO , Nov. 20, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 53 of its Science Bytes podcast, featuring Qian Ding, MD, PhD, Senior Medical Affairs Manager, QuidelOrtho, an expert in clinical and laboratory medicine with deep experience in healthcare information systems and data analytics. In the episode titled "Don't Wait for the Wake-Up Call," Dr. Ding explains why early detection of diabetes is a clinical and economic priority.

PRNewsWire • Nov 20, 2025

QuidelOrtho Corporation (QDEL) Q3 2025 Earnings Call Transcript

QuidelOrtho Corporation ( QDEL ) Q3 2025 Earnings Call November 5, 2025 5:00 PM EST Company Participants Juliet Cunningham - Vice President of Investor Relations Brian Blaser - President, CEO & Director Joseph Busky - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair & Company L.L.C., Research Division Lu Li - UBS Investment Bank, Research Division Jack Meehan - Nephron Research LLC Jack Melick - Jefferies LLC, Research Division Andrew Cooper - Raymond James & Associates, Inc., Research Division Presentation Operator Welcome to the QuidelOrtho Third Quarter 2025 Financial Results Conference Call and webcast.

Seeking Alpha • Nov 6, 2025

QuidelOrtho Q3 Earnings and Revenues Beat Estimates, Margins Expand

QDEL tops Q3 estimates as Labs and Immunohematology units drive growth, while margins strengthen despite respiratory revenue declines.

Zacks Investment Research • Nov 6, 2025

QuidelOrtho Reports Third Quarter 2025 Financial Results

―  Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum ― ― Successful completion of debt refinancing, enhancing financial flexibility through improved terms and reduced amortization obligations ― ― Full-year 2025 revenue and adjusted EBITDA guidance ranges narrowed; adjusted diluted EPS updated to reflect debt refinancing ―  Third Quarter 2025 Results (all comparisons are to the prior year period)                                   Total revenue was $700 million, as reported Non-respiratory revenue was $588 million, an increase of 5% as reported and 4% in constant currency; excluding Donor Screening1, non-respiratory revenue grew 6% in constant currency Labs revenue grew 5% as reported and 4% in constant currency Respiratory revenue was $112 million as reported; the decline was primarily driven by a 63% decrease in COVID-19 revenue GAAP operating expenses2 decreased by 6%; non-GAAP operating expenses decreased by 7%, both driven by the Company's cost-savings initiatives GAAP net loss margin was (105%); GAAP operating margin was (101%), which included a $701 million non-cash goodwill impairment charge (see description below); adjusted EBITDA margin was 25%, a 180 basis point improvement compared to the prior year period GAAP diluted loss per share was $10.78; adjusted diluted earnings per share ("EPS") was $0.80 SAN DIEGO , Nov. 5, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the third quarter ended September 28, 2025. "Our third quarter results reflect continued execution and meaningful progress against our strategic and financial priorities," said Brian J.

PRNewsWire • Nov 5, 2025

QuidelOrtho Receives FDA 510(k) Clearance for VITROS™ Immunodiagnostic Products hs Troponin I Assay

Clearance expands menu and enables high-sensitivity troponin I measurement to aid in the diagnosis of myocardial infarction SAN DIEGO , Nov. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global leader of in vitro diagnostics, 510(k) clearance for the VITROS hs Troponin I Reagent Pack (the "VITROS hs Troponin I Assay"). The assay is intended for the quantitative measurement of cardiac troponin I (cTnI) in human plasma (heparin) to aid in the diagnosis of myocardial infarction (MI).

PRNewsWire • Nov 3, 2025

Informatics Illuminated: Science Bytes Podcast Explores the Power Behind Smarter Diagnostics

SAN DIEGO , Oct. 23, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 52 of its Science Bytes podcast, featuring George Wierschem, MBA, MT(ASCP), Senior Global Product Manager – Informatics. In the episode titled "The Power of Informatics in Clinical Decision-Making," Wierschem shares how informatics platforms are transforming laboratory operations by connecting instruments, data systems and clinical decisions.

PRNewsWire • Oct 23, 2025

QuidelOrtho to Report Third Quarter 2025 Financial Results

SAN DIEGO , Oct. 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its financial results for the third quarter 2025 ended September 28, 2025, after the market closes on Wednesday, November 5, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m.

PRNewsWire • Oct 22, 2025